mRNA-1345 is an investigational vaccine for the prevention of RSV in adults aged 60 years or older TORONTO – Moderna Biopharma Canada Corp. has announced the filing of a New Drug Submission (NDS) to Health Canada for mRNA-1345, its investigational vaccine candidate for the prevention of RSV in adults aged 60 years or older. This is the first mRNA vaccine …